OBJECTIVE: To find novel inhibitors of mast cell function we have studied the effect of a potent, non-antimicrobial, chemically modified tetracycline, CMT-3 or COL-3, on key functions of mast cells. METHODS AND RESULTS: In the presence of 25 microM CMT-3, the 48/80-induced histamine release from rat serosal mast cells was inhibited significantly, to 43.0 +/- 7.3% of control. Similarly, the activation-induced secretion of TNF-alpha and IL-8 by HMC-1 cells were decreased in the presence of 25 microM CMT-3 to 13.5 +/- 4.1% and 9.7 +/- 1.1% of control, respectively. CMT-3 did not cause intracellular accumulation of TNF-alpha but instead it reduced the expression of TNF-alpha mRNA in HMC-1 cells. Moreover, CMT-3 was found to significantly inhibit the protein kinase C (PKC) activity with IC(50) value of 31 microM. CMT-3 inhibited effectively both human recombinant PKCalpha and PKCdelta isoforms. In comparison to doxycycline, CMT-3 was more effective as an inhibitor of both cytokine production and PKC activity. CONCLUSIONS: Considering the central role of PKC in mast cell activation, PKC inhibition could, at least partially, explain the observed inhibitory effects of CMT-3. The inhibition of the key proinflammatory functions of mast cells by CMT-3 suggests its potential clinical usefulness in the treatment of allergic and inflammatory disorders.
OBJECTIVE: To find novel inhibitors of mast cell function we have studied the effect of a potent, non-antimicrobial, chemically modified tetracycline, CMT-3 or COL-3, on key functions of mast cells. METHODS AND RESULTS: In the presence of 25 microM CMT-3, the 48/80-induced histamine release from rat serosal mast cells was inhibited significantly, to 43.0 +/- 7.3% of control. Similarly, the activation-induced secretion of TNF-alpha and IL-8 by HMC-1 cells were decreased in the presence of 25 microM CMT-3 to 13.5 +/- 4.1% and 9.7 +/- 1.1% of control, respectively. CMT-3 did not cause intracellular accumulation of TNF-alpha but instead it reduced the expression of TNF-alpha mRNA in HMC-1 cells. Moreover, CMT-3 was found to significantly inhibit the protein kinase C (PKC) activity with IC(50) value of 31 microM. CMT-3 inhibited effectively both human recombinant PKCalpha and PKCdelta isoforms. In comparison to doxycycline, CMT-3 was more effective as an inhibitor of both cytokine production and PKC activity. CONCLUSIONS: Considering the central role of PKC in mast cell activation, PKC inhibition could, at least partially, explain the observed inhibitory effects of CMT-3. The inhibition of the key proinflammatory functions of mast cells by CMT-3 suggests its potential clinical usefulness in the treatment of allergic and inflammatory disorders.
Authors: Leandro F S Bastos; Antônio C P de Oliveira; Linda R Watkins; Márcio F D Moraes; Márcio M Coelho Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-01-27 Impact factor: 3.000
Authors: Shreyas K Roy; Daniel Kendrick; Benjamin D Sadowitz; Louis Gatto; Kathleen Snyder; Joshua M Satalin; Lorne M Golub; Gary Nieman Journal: Pharmacol Res Date: 2011-06-21 Impact factor: 7.658
Authors: Heather L Benson; Shahriar Mobashery; Mayland Chang; Farrah Kheradmand; Jeong Soo Hong; Gerald N Smith; Rebecca A Shilling; David S Wilkes Journal: Am J Respir Cell Mol Biol Date: 2010-07-16 Impact factor: 6.914
Authors: L F S Bastos; A Angusti; M C Vilaça; L A Merlo; E B Nascimento; L T S Rocha; A M Godin; A G R Solano; S Jarussophon; E A Nunan; Y Konishi; M M Coelho Journal: Br J Pharmacol Date: 2008-07-28 Impact factor: 8.739
Authors: Amarjit S Naura; Hogyoung Kim; Jihang Ju; Paulo C Rodriguez; Joaquin Jordan; Andrew D Catling; Bashir M Rezk; Zakaria Y Abd Elmageed; Kusma Pyakurel; Abdelmetalab F Tarhuni; Mohammad Q Abughazleh; Youssef Errami; Mourad Zerfaoui; Augusto C Ochoa; A Hamid Boulares Journal: J Biol Chem Date: 2012-11-26 Impact factor: 5.157
Authors: Milla Summanen; Niko Granqvist; Raimo K Tuominen; Marjo Yliperttula; C Theo Verrips; Johannes Boonstra; Christophe Blanchetot; Elina Ekokoski Journal: PLoS One Date: 2012-04-20 Impact factor: 3.240